US 12,324,856 B2
Oral drug dosage form comprising drug in the form of nanoparticles
Xiaoling Li, Dublin, CA (US)
Assigned to Triastek, Inc., Nanjing (CN)
Filed by Triastek, Inc., Nanjing (CN)
Filed on Mar. 10, 2021, as Appl. No. 17/197,204.
Application 17/197,204 is a division of application No. 16/289,499, filed on Feb. 28, 2019, granted, now 10,973,767.
Application 16/289,499 is a continuation of application No. 16/028,305, filed on Jul. 5, 2018, granted, now 10,258,575, issued on Apr. 16, 2019.
Application 16/028,305 is a continuation of application No. 15/173,596, filed on Jun. 3, 2016, granted, now 10,363,220, issued on Jul. 30, 2019.
Claims priority of provisional application 62/313,092, filed on Mar. 24, 2016.
Claims priority of provisional application 62/296,087, filed on Feb. 17, 2016.
Claims priority of provisional application 62/170,645, filed on Jun. 3, 2015.
Prior Publication US 2021/0205226 A1, Jul. 8, 2021
Int. Cl. A61K 9/20 (2006.01); A61K 9/00 (2006.01); A61K 9/24 (2006.01); A61K 31/192 (2006.01)
CPC A61K 9/2031 (2013.01) [A61K 9/0065 (2013.01); A61K 9/2027 (2013.01); A61K 9/2072 (2013.01); A61K 9/209 (2013.01); A61K 31/192 (2013.01)] 19 Claims
OG exemplary drawing
 
1. A tablet comprising:
i) a first substrate layer, a second substrate layer, and a third substrate layer, wherein each substrate layer comprises a substrate;
ii) a first nanoparticle layer comprising nanoparticles consisting of a first drug; and
iii) a second nanoparticle layer comprising nanoparticles consisting of a second drug;
wherein the tablet has a multi-layered structure from top to bottom: the first substrate layer, the first nanoparticle layer, the second substrate layer, the second nanoparticle layer, and the third substrate layer; and
wherein the first drug and the second drug are capable of being continuously released from a lateral side of the tablet.